A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin.
Phase of Trial: Phase III
Latest Information Update: 23 May 2016
At a glance
- Drugs Vonoprazan (Primary) ; Lansoprazole
- Indications Duodenal ulcer; Gastric ulcer; NSAID-induced ulcer
- Focus Adverse reactions
- Sponsors Takeda
- 25 Jun 2014 Status changed from recruiting to completed.
- 20 Mar 2014 New trial record